Industries / Health / Healthcare / Direct primary care
Labs and drugs at cost
Practices buy lab tests, generic drugs and some imaging at wholesale or negotiated cash prices and pass them on to members, often near cost, so members can skip insurance for those items.
5
Milestones achieved, from 2000 to 2022.
1
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
2000
Korea splits prescribing and dispensing
In 2000 South Korea put into force the separation of drug prescribing and dispensing, summed up as "doctors prescribe, pharmacists dispense", so that clinics stopped handing out the drugs their doctors ordered. The legal basis dated from 1963. By the late 1990s antibiotic overuse, irrational prescribing and conflicts of interest in physician dispensing had made it a patient-safety issue, and nationwide physician strikes after it took effect did not reverse it, by the account of a 2026 commentary in Frontiers in Public Health.
Lessonwhere doctors earned money on the drugs they handed out, the public backed taking dispensing away from them, even through strikes.
Credit
the South Korean government
2009
Surgery prices posted online
The Surgery Center of Oklahoma, an ambulatory surgery center in Oklahoma City owned by about 40 surgeons and anesthesiologists, opened in 1997 and quoted all-inclusive cash prices by phone. In 2009 its co-founder, Keith Smith, put the prices on its website. In 2013 The New York Times listed $6,990 for a knee ligament (ACL) reconstruction and $3,600 for a tonsillectomy, paid in advance, and reported that other Oklahoma facilities had begun posting prices. In 2025 Senate testimony Smith said about half the center's patients travel from other states or countries. Eskew and Klink wrote in 2015 that direct primary care doctors negotiate such cash prices for uninsured members who need procedures such as a colonoscopy or an MRI scan.
Credit
Keith Smith and the surgeon owners of the Surgery Center of Oklahoma
2017
Dispensing caps get sidestepped
In US workers' compensation, where an insurer pays, some doctors dispense drugs in the office, often bought in bulk and repackaged under a new national drug code. The Workers Compensation Research Institute (WCRI) found in 2014, across 24 states and more than 600,000 claims, that office-dispensed drugs cost more than the same drugs from a pharmacy: hydrocodone with acetaminophen (Vicodin) cost $1.46 a pill from a doctor, four times the pharmacy price. States changed how they paid for doctor-dispensed repackaged drugs. WCRI's 2017 study of 26 states (2011 to 2014) found that the changes cut prices for existing products, but prices rose again in California, Florida and Illinois as doctors dispensed new strengths that the rules did not reach.
Lessona price rule written around product codes was sidestepped with new product codes.
Credit
Workers Compensation Research Institute (Dongchun Wang and colleagues)
2021
Montana lifts its dispensing ban
Montana law had made it "unlawful for a medical practitioner to engage, directly or indirectly, in the dispensing of drugs", except in emergencies, where no community pharmacy was available, or occasionally. The Institute for Justice sued on behalf of Montana doctors in June 2020, by DPC Frontier's account, and a 2021 amendment (Chapter 454, Laws of 2021) let a practitioner register with the board of pharmacy and dispense to their own patients at the office, after offering a prescription the patient can fill anywhere, with no controlled substances. Other states still limit it: by DPC Frontier's state guide, Massachusetts prohibits office dispensing, New York allows at most a 72-hour supply, and New Jersey allows a seven-day supply at or below cost plus an administrative charge of up to 10%. In the AAFP's 2026 survey, 54% of membership practices dispensed non-controlled drugs in the office, down from 65% in 2022.
Credit
the Montana Legislature; the Institute for Justice
2022
Generics at cost plus 15%
Mark Cuban Cost Plus Drug Company opened online in January 2022, selling more than 100 generic drugs for cash at the manufacturer's price plus a flat 15% margin, a pharmacist fee and shipping, without taking insurance. Hussain Lalani and colleagues at Brigham and Women's Hospital, writing in the Annals of Internal Medicine in 2022, estimated that Medicare would have saved $3.3 billion (36%) on 77 of 89 generic drugs in 2020 had it paid Cost Plus prices; those drugs were 25% of about $38 billion in Medicare Part D generic spending. In 2026 John Lin and colleagues at MD Anderson Cancer Center matched 60,200,969 commercial generic drug claims from 2024 with 2025 Cost Plus prices: buying there would have saved patients a median of $6 on about 15% of prescriptions, and 80% of generics with cost sharing of at least $15 would have cost them less.
Credit
Mark Cuban Cost Plus Drug Company; Hussain Lalani and colleagues; John Lin and colleagues
Watch for
Generics through a government site
TrumpRx.gov, the US government's cash-price drug website, launched in February 2026 with brand-name deals. In May 2026 the administration said about 600 generic drugs would be bought through it, 559 of them from Mark Cuban Cost Plus Drug Company by the Washington Post's count, with Amazon Pharmacy and GoodRx as other routes, and that the site had recorded more than 10 million visits.
Achieved whenan outside party publishes how many generic prescriptions were bought through the site and how their prices compare with buying the same drugs from the sellers directly.
Claimed by
the Trump administration, May 2026
Open
01
Lab price sheets, checked
A public table of the cash lab prices that direct primary care practices post for their members, for the 30 most commonly ordered tests, matched by CPT code (the standard US billing code for each test), set beside Medicare's Clinical Laboratory Fee Schedule rate for the same code and the cash prices nearby hospitals post. Each price carries its source document and date.
The briefCredit · unclaimed02
At-cost drug lists, checked
A comparison of the prices practices post for drugs they dispense in the office with NADAC, the weekly national average of what US pharmacies pay for each drug, and with Cost Plus Drugs' posted price for the same drug, strength and quantity, to measure how close "at cost" lists are to acquisition cost. Data only; no drug is bought, dispensed or recommended.
The briefCredit · unclaimed
Open 01 · the brief
Lab price sheets, checked
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public table of the cash lab prices that direct primary care practices post for their members, for the 30 most commonly ordered tests, matched by CPT code (the standard US billing code for each test), set beside Medicare's Clinical Laboratory Fee Schedule rate for the same code and the cash prices nearby hospitals post. Each price carries its source document and date.
Why it is still open
Practices do publish price sheets. Fischer Clinic's February 2020 sheet, filed with a North Carolina legislative committee, lists LabCorp tests for members at $4 for a basic metabolic panel, $4 for a lipid panel and $4 for a hemoglobin A1c. Elation Health's guide says such prices come from negotiated "client bill" rates, where the lab bills the practice, and that in 2021 19 states had laws requiring labs to bill the patient directly; DPC Frontier says client billing is "difficult or not possible" in New York and New Jersey. The Health Care Cost Institute found that employer insurance paid a median $9.73 for a lipid panel at independent labs and $35 at hospital outpatient departments in 2022, but that study covers insured claims, not cash prices. A search found no study comparing posted practice prices with Medicare's rates; published figures come from practice blogs. Medicare's fee schedule is set from the weighted median of private insurers' rates, which makes it a public measure of what insurers pay.
webservices.ncleg.govelationhealth.comdpcfrontier.comhealthcostinstitute.orgcms.gov
Built with what exists
Practice websites found through the DPC Frontier mapper; pdftotext and an AI model to read price tables from PDFs into rows (the site's Note "Seven more flagged" covers Claude reviewing long documents); the CMS Clinical Laboratory Fee Schedule files; hospitals' machine-readable standard-charge files; LabCorp's and Quest's public test menus to map test numbers to CPT codes.
First step
Collect 50 price sheets from mapper listings in five states and build the CPT crosswalk for the 30 tests.
Done looks like
At least 150 practices in at least 25 states, 30 tests each where posted, every price linked to its source; the median ratio of practice price to Medicare rate for each test and state; a second person re-checks a random 10% of rows and agrees on at least 98%.
Open 02 · the brief
At-cost drug lists, checked
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A comparison of the prices practices post for drugs they dispense in the office with NADAC, the weekly national average of what US pharmacies pay for each drug, and with Cost Plus Drugs' posted price for the same drug, strength and quantity, to measure how close "at cost" lists are to acquisition cost. Data only; no drug is bought, dispensed or recommended.
Why it is still open
Selling at cost is advertised widely, and New Jersey writes a ceiling into law (cost plus up to 10%). The outside measurements so far compare Cost Plus with Medicare spending or with commercial claims, or compare doctor-dispensed workers' compensation drugs with pharmacy prices; none found checks direct primary care practices' posted lists.
Built with what exists
The NADAC 2026 weekly files on data.medicaid.gov; Cost Plus Drugs' public price pages; posted dispensary lists from practices in states that allow office dispensing; the National Library of Medicine's RxNorm to match drug names and strengths; Python.
First step
Download this week's NADAC file and code the dispensary lists of 20 practices in five states.
Done looks like
Lists from at least 100 practices, at least 50 drugs matched in each; the share of list prices within 10% and within 25% of NADAC per unit, and the share above the Cost Plus price; data and code published.